Hikma Pharmaceuticals Balances Profit Strength With Injectables Reset

Hikma Pharmaceuticals ((GB:HIK)) has held its Q4 earnings call. Read on for the main highlights of the call.

Hikma Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone, balancing robust group performance with clear acknowledgment of near-term challenges in its injectables franchise. Management emphasized strong profitability, leadership in MENA, and momentum in Europe and generics, while preparing investors for a period of investment-led margin pressure ahead of a planned step-up in growth post-2027.

Group Profitability Stands Out Versus Peers

Hikma reported a group EBITDA margin of around 25%, materially ahead of peers that typically target about 22%. This gap underlines solid operational leverage and disciplined cost control across the portfolio, giving the company financial firepower to invest even as it absorbs headwinds in injectables.

Rx Generics Turnaround Delivers Above-Plan Margins

The Rx generics division has transformed into a high-margin engine, now delivering close to 20% margins with EBIT of roughly GBP 200 million. Management reminded investors that previous EBIT ambitions were just GBP 100–130 million, signaling that the turnaround has significantly outperformed earlier expectations.

MENA Leadership and Branded Growth Accelerate

Hikma secured the number-one position in the MENA region this year, reinforcing its strategic strength in branded markets. The branded business is now growing at about 7–8%, up from a historical 5–6%, driven by licensing partnerships and continued regional expansion.

Europe Injectables Benefit From Strong Demand

European injectables grew about 23% this year, supported by robust hospital and government demand. Management highlighted Hikma’s supply reliability and differentiated execution as key reasons it is winning share and contracts in a market where continuity of supply is critical.

RTU Platform and TYZAVAN Gain Early Traction

The ready-to-use platform now includes roughly 15 products in development, with TYZAVAN (vancomycin RTU) showing encouraging initial performance. The product has converted around 13% of the gram market for the existing vancomycin bag, and current customers represent about 15% of an estimated 22,000 target sites.

R&D Centralization and Spending Uplift

Hikma has moved its R&D budget to the corporate level and lifted spending to about 5–6% of group sales. This implies an increase of roughly $45 million year-on-year, including about GBP 15 million more for injectables, as management accelerates pipeline development and aims to build a more innovation-driven portfolio.

Strategic CMO Expansion and Capital Returns

Contract manufacturing is emerging as a strategic pillar, with Rx CMO already representing around 10% of the business this year. Hikma aims to lift CMO’s contribution to as much as 20% by 2030 while also returning capital via a GBP 250 million share buyback, underscoring confidence in cash generation.

Injectables Margin Reset Reflects Investment Phase

Injectables margins have stepped down from the mid-30s to the high-20s to low-30s range, a 2–3 percentage point drag versus prior expectations. Management linked this to higher R&D, increased sales and marketing, and CMO-related changes, describing it as a deliberate reset to support future growth.

2025–2026 to Be Tough Years for Injectables

The company flagged 2025 and 2026 as transition years for injectables, with several launches pushed out and some key RTU products now slated for early 2028. This delay shifts anticipated top-line contributions further into the future, tempering near-term growth expectations for the division.

Short-Term CMO Volume Loss Hits Revenue

Hikma has seen reduced CMO volumes after at least one major customer moved manufacturing to the U.S., creating a revenue headwind. The Bedford and Xellia capacity build-outs, which are critical to scaling U.S. CMO operations, are not expected to be fully operational until around 2028.

Pricing Pressure Adds to Injectable Margin Strain

Management noted pricing erosion across parts of the injectable portfolio, though excluding the top two products, price declines were contained to low- to mid-single-digit levels. An erosion rate of around 4% still weighs on margins, especially when combined with higher investment and temporarily lower CMO utilization.

Long Lead Times Heighten Capacity Upgrade Risk

Reengineering the Bedford site and procuring new lines involve long lead times, with equipment taking up to 1.5–2 years to arrive, qualify, and receive approvals. This operational reality introduces timing risk and pushes the full benefit of expanded U.S. CMO capacity toward the latter part of the decade.

Intentional Margin Sacrifice to Fund Growth

By centralizing R&D and increasing spend alongside broader sales, marketing, and supply-chain investments, Hikma is accepting lower near-term divisional margins. Management framed this as a conscious trade-off, aimed at securing higher medium- and long-term growth once new capacity and pipelines fully ramp.

Guidance Points to Stronger Growth From 2027–28

Management reiterated comfort with 2026 guidance while keeping an aspirational GBP 5 billion revenue target for 2030, anchored by a robust 25% group EBITDA margin. With R&D lifted to 5–6% of sales, CMO targeted to grow from roughly 10% to about 20% of revenue by 2030, and major Bedford/Xellia capacity expected online by 2028, Hikma expects injectables and overall growth to strengthen meaningfully from 2027–28 onward.

Hikma’s earnings call outlined a company in investment mode, leveraging strong group profitability, a revitalized generics business, and MENA and European momentum to fund a reset in injectables. While investors should brace for a couple of tougher years, management’s clear road map for capacity, pipeline, and CMO expansion supports a cautiously optimistic view of Hikma’s longer-term value creation potential.